Wednesday, 15 Aug 2018

You are here

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH  (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Researchers from Oregon State and Oregon Health Science University performed a cross-sectional analysis of data from the Centers for Medicare & Medicaid Services 2015 Part D prescribing data that was further linked to 2015 Open Payments data. 

The data set include 2015 nephrologists, neurologists, and rheumatologists who had more than 10 corticotropin prescriptions. This included a total of 235 included physicians; 65 were nephrologists; 59 neurologists; and 111 rheumatologists.

Of these 235 specialists, 207 (88%) received a monetary payment from the drug’s maker, Mallinckrodt.  Physician payments ranged from $11-$138 321 in 2015. More 20% of frequent prescribers receiving more than $10 000. Maximum total payments were highest for rheumatology ($138 321) compared to nephrology ($56 549) and neurology ($120 387).

There was a significant association between higher dollar amounts paid to these prescribers and greater Medicare spending on their corticotropin prescriptions.

For every $10 000 in physician payments, there was an associated 7.9% increase (approximately $53 000) in Medicare spending on corticotropin. There was no association between corticotropin-related payments and spending on prescriptions for synthetic corticosteroids.

It appears there are significant financial conflicts of interest among physicians who treat Medicare patients with corticotropin therapy.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

Jack It is unfortunate and sad that obvious and subtle conflicts of interest with regard to drug choice are so common in rheumatology and medicine in general. I am surprised however that insurance companies are not limiting the use of Acthar, since they seem to do so with many highly effective and appropriate therapies. Art

More Like This

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.

Best of 2017: New EULAR Guidelines on Behçet's

At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented. These were developed by a multidisciplinary expert committee that reviewed the evidence from the medical literature and developed final set of 9 recommendations:

EULAR 2018 - Day 3 Report

Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well.